Femasys Inc.

What they do

Femasys designs, manufactures, and sells in-office therapeutic and diagnostic products for women's health, focusing on infertility and permanent birth control. Its commercial portfolio includes FemaSeed (intratubal insemination), FemVue/FemVue Controlled (fallopian tube assessment), FemCerv (endocervical sampling), FemChec (ultrasound confirmation), and FemSperm (sperm preparation kits). The company also develops FemBloc, a non-surgical permanent birth control system, which is approved in the EU, UK, and New Zealand but not yet in the U.S.

Revenue drivers

• FemaSeed fertility products — Intratubal insemination devices, including FemaSeed Complete; drove the slight sales increase in 1H 2026.
• FemVue diagnostic products — Ultrasound-based fallopian tube assessment devices; sales declined in Q2 2026, contributing to an 18.9% drop in quarterly revenue.
• FemBloc (EU/UK/NZ) — Non-surgical permanent birth control system; regulatory approvals and distribution partnerships in Spain and France/Benelux expected to generate revenue, though not yet material.

Recent performance

For the quarter ended June 30, 2026, revenue was $331,827, down 18.9% from $409,268 in the year-ago quarter, attributed to lower FemVue sales. Net loss for the quarter narrowed slightly to $4,469,095 from $4,585,922 in 2025. For the six months ended June 30, 2026, sales rose 0.8% to $756,716 from $750,532, while net loss improved to $3,622,995 from $10,482,761. Cash and cash equivalents were $1.4 million as of June 30, 2026, with an accumulated deficit of $149.4 million. Fiscal 2025 full-year revenue was $2.3 million with an $18.6 million net loss.

Strategy

Management is focused on U.S. commercial expansion of the FemaSeed fertility portfolio, including the recent launch of FemaSeed Complete with OB/GYNs. The company is advancing FemBloc’s U.S. pivotal clinical trial, which began enrollment in March 2026, toward final FDA approval. Internationally, it is building distribution partnerships (e.g., Spain, France/Benelux, Israel) and leveraging recent CE Marks for FemBloc components and FemHSG Catheter. A $30 million private placement (with potential for up to $90 million if warrants are exercised) is intended to fund operations, commercial initiatives, and clinical milestones. The company also appointed a COO and is strengthening its patent portfolio and U.S. manufacturing capabilities.

Risks

• Liquidity risk — As of June 30, 2026, cash was only $1.4 million, and management previously estimated funds would last only into Q3 2026; the new $30 million financing may not be sufficient for all planned activities.
• Clinical and regulatory dependency — FemBloc's U.S. approval requires successful completion of the pivotal trial, and any delays or adverse results could materially harm the company's prospects.
• Commercial execution risk — Revenue is small and product-line dependent; Q2 2026 sales fell 18.9% due to lower FemVue sales, indicating limited and uneven commercial traction.
• Going concern risk — The company has incurred net losses every year since inception and expects continued losses; its accumulated deficit at June 30, 2026, was $149.4 million.

Outlook

Management is optimistic that the $30 million private placement will support commercial execution of the fertility portfolio and the FemBloc clinical program through key milestones. It expects to continue enrollment in the FemBloc U.S. pivotal trial and seeks final FDA approval. The company plans to leverage recent international approvals and distribution partnerships to expand revenue. However, given the small revenue base and ongoing losses, the outlook depends heavily on raising additional capital and achieving regulatory and commercial success.